title: BDNF polymorphism rs11030101 is associated with the efficacy of electroconvulsive therapy in treatment-resistant depression.
abstract: The aim of the present study was to test for a possible association between two brain-derived neurotrophic factor (BDNF) polymorphisms (rs11030101 and rs61888800) and the efficacy of electroconvulsive therapy (ECT) [change in Montgomery-Åsberg Depression Rating Scale (MADRS)]. So far, there are no studies investigating an association between these polymorphisms and the efficacy of ECT. The patient sample included 119 patients with treatment-resistant major depressive disorder who were treated with ECT. BDNF polymorphism rs11030101, but not rs61888800, was associated with a change in the MADRS score. Patients with the TA genotype of rs11030101 were less likely to benefit from ECT compared with patients with the TT genotype (P=0.041). The finding suggests an association between BDNF polymorphism rs11030101 and the efficacy of ECT. Further studies with larger samples will be required to confirm this finding.
authors.affiliation: Department of Psychiatry, Medical School, University of Tampere, Tampere, Finland. merja.viikki@gmail.com
authors.forename: Merja L
authors.initials: ML
authors.lastname: Viikki
authors.forename: Kaija
authors.initials: K
authors.lastname: Järventausta
authors.forename: Esa
authors.initials: E
authors.lastname: Leinonen
authors.forename: Martti
authors.initials: M
authors.lastname: Huuhka
authors.forename: Nina
authors.initials: N
authors.lastname: Mononen
authors.forename: Terho
authors.initials: T
authors.lastname: Lehtimäki
authors.forename: Olli
authors.initials: O
authors.lastname: Kampman
mesh_terms: D000328:Adult; D019208:Brain-Derived Neurotrophic Factor / Q000235:genetics*; D016022:Case-Control Studies; D003863:Depression / Q000235:genetics / Q000628:therapy*; D004565:Electroconvulsive Therapy; D006801:Humans; D008875:Middle Aged; D011110:Polymorphism, Genetic
chemical_list: D019208:Brain-Derived Neurotrophic Factor